Trial Profile
Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 15 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
- 23 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.